Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2006 1
2010 2
2012 3
2013 2
2014 2
2015 5
2016 3
2017 6
2018 10
2019 10
2020 6
2021 9
2022 14
2023 20
2024 5

Text availability

Article attribute

Article type

Publication date

Search Results

74 results

Results by year

Filters applied: . Clear all
Quoted phrase not found in phrase index: "Hypertrophic cardiomyopathy 3"
Page 1
Mavacamten Treatment for Hypertrophic Cardiomyopathy: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
Ismayl M, Abbasi MA, Marar R, Geske JB, Gersh BJ, Anavekar NS. Ismayl M, et al. Curr Probl Cardiol. 2023 Jan;48(1):101429. doi: 10.1016/j.cpcardiol.2022.101429. Epub 2022 Sep 24. Curr Probl Cardiol. 2023. PMID: 36167226 Review.
Hypertrophic cardiomyopathy (HCM) is the most common heritable cardiomyopathy, yet pharmacological therapy has been unchanged for decades until the recent introduction of mavacamten, a first-in-class cardiac myosin inhibitor. We assessed the efficacy and safe …
Hypertrophic cardiomyopathy (HCM) is the most common heritable cardiomyopathy, yet pharmacological therapy has been unc …
Prevalence and clinical outcomes of transthyretin amyloidosis: a systematic review and meta-analysis.
Antonopoulos AS, Panagiotopoulos I, Kouroutzoglou A, Koutsis G, Toskas P, Lazaros G, Toutouzas K, Tousoulis D, Tsioufis K, Vlachopoulos C. Antonopoulos AS, et al. Eur J Heart Fail. 2022 Sep;24(9):1677-1696. doi: 10.1002/ejhf.2589. Epub 2022 Aug 2. Eur J Heart Fail. 2022. PMID: 35730461 Free article.
We identified a total of 62 studies (n = 277 882 individuals) reporting the prevalence of cardiac amyloidosis, which was high among patients with a hypertrophic cardiomyopathy phenotype, heart failure with preserved ejection fraction, and the elderly with aortic ste …
We identified a total of 62 studies (n = 277 882 individuals) reporting the prevalence of cardiac amyloidosis, which was high among patients …
Redefining the epidemiology of cardiac amyloidosis. A systematic review and meta-analysis of screening studies.
Aimo A, Merlo M, Porcari A, Georgiopoulos G, Pagura L, Vergaro G, Sinagra G, Emdin M, Rapezzi C. Aimo A, et al. Eur J Heart Fail. 2022 Dec;24(12):2342-2351. doi: 10.1002/ejhf.2532. Epub 2022 May 16. Eur J Heart Fail. 2022. PMID: 35509173 Free PMC article.
The prevalence of CA in different settings was as follows: bone scintigraphy for non-cardiac reasons (n = 5 studies), 1% (95% confidence interval [CI] 0%-1%); heart failure with preserved ejection fraction (n = 6), 12% (95% CI 6%-20%); heart failure with reduced or mildly reduced …
The prevalence of CA in different settings was as follows: bone scintigraphy for non-cardiac reasons (n = 5 studies), 1% (95% confidence int …
Assessment of Postnatal Corticosteroids for the Prevention of Bronchopulmonary Dysplasia in Preterm Neonates: A Systematic Review and Network Meta-analysis.
Ramaswamy VV, Bandyopadhyay T, Nanda D, Bandiya P, Ahmed J, Garg A, Roehr CC, Nangia S. Ramaswamy VV, et al. JAMA Pediatr. 2021 Jun 1;175(6):e206826. doi: 10.1001/jamapediatrics.2020.6826. Epub 2021 Jun 7. JAMA Pediatr. 2021. PMID: 33720274 Free PMC article.
Surface under the cumulative ranking curve (SUCRA) value ranking showed that MoMdDX (SUCRA, 0.91), MoHdDX (SUCRA, 0.86), and LaHdDX (SUCRA, 0.76) were the 3 most beneficial interventions. ITBUD (RR, 4.36; 95% CrI, 1.04-12.90); LaHdDX (RR, 11.91; 95% CrI, 1.64-44.49); LaLdD …
Surface under the cumulative ranking curve (SUCRA) value ranking showed that MoMdDX (SUCRA, 0.91), MoHdDX (SUCRA, 0.86), and LaHdDX (SUCRA, …
Hypertrophic Cardiomyopathy and Atrial Fibrillation: A Systematic Review and Meta-analysis of Anticoagulation Strategy.
Oliveri F, Pepe A, Bongiorno A, Fasolino A, Gentile FR, Schirinzi S, Colombo D, Breviario F, Greco A, Turco A, Acquaro M, Tua L, Scelsi L, Ghio S. Oliveri F, et al. Am J Cardiovasc Drugs. 2023 May;23(3):269-276. doi: 10.1007/s40256-023-00580-x. Epub 2023 Apr 15. Am J Cardiovasc Drugs. 2023. PMID: 37061614
BACKGROUND: Atrial fibrillation (AF) frequently complicates hypertrophic cardiomyopathy (HCM), and anticoagulation significantly decreases the risk of stroke in this population. ...
BACKGROUND: Atrial fibrillation (AF) frequently complicates hypertrophic cardiomyopathy (HCM), and anticoagulation significant …
Syncope in hypertrophic cardiomyopathy (part I): An updated systematic review and meta-analysis.
Mascia G, Crotti L, Groppelli A, Canepa M, Merlo AC, Benenati S, Di Donna P, Della Bona R, Soranna D, Zambon A, Porto I, Olivotto I, Parati G, Brignole M, Cecchi F. Mascia G, et al. Int J Cardiol. 2022 Jun 15;357:88-94. doi: 10.1016/j.ijcard.2022.03.028. Epub 2022 Mar 15. Int J Cardiol. 2022. PMID: 35304190 Review.
AIMS: To describe the proportion of patients with syncope among those affected by hypertrophic cardiomyopathy (HCM) and the relevance of syncope as risk factor for sudden cardiac death and life-threatening arrhythmic events. ...Life-threatening arrhythmic events occ …
AIMS: To describe the proportion of patients with syncope among those affected by hypertrophic cardiomyopathy (HCM) and the re …
Current therapies for hypertrophic cardiomyopathy: a systematic review and meta-analysis of the literature.
Bayonas-Ruiz A, Muñoz-Franco FM, Sabater-Molina M, Oliva-Sandoval MJ, Gimeno JR, Bonacasa B. Bayonas-Ruiz A, et al. ESC Heart Fail. 2023 Feb;10(1):8-23. doi: 10.1002/ehf2.14142. Epub 2022 Oct 1. ESC Heart Fail. 2023. PMID: 36181355 Free PMC article. Review.
AIMS: The aim of this study was to synthesize the evidence on the effect of the current therapies over the pathophysiological and clinical characteristics of patients with hypertrophic cardiomyopathy (HCM). METHODS AND RESULTS: A systematic review and meta-analysis …
AIMS: The aim of this study was to synthesize the evidence on the effect of the current therapies over the pathophysiological and clinical c …
A systematic review of microRNAs in patients with hypertrophic cardiomyopathy.
Scolari FL, Faganello LS, Garbin HI, Piva E Mattos B, Biolo A. Scolari FL, et al. Int J Cardiol. 2021 Mar 15;327:146-154. doi: 10.1016/j.ijcard.2020.11.004. Epub 2020 Nov 16. Int J Cardiol. 2021. PMID: 33212095
BACKGROUND: Several microRNAs (miRNA) have been associated with hypertrophic cardiomyopathy (HCM), but studies differ regarding methods employed. ...METHODS: The literature search was based on The Medical Subject Headings (MeSH) terms "Hypertrophic Cardiom …
BACKGROUND: Several microRNAs (miRNA) have been associated with hypertrophic cardiomyopathy (HCM), but studies differ regardin …
Efficacy and Safety of Mavacamten in the Treatment of Hypertrophic Cardiomyopathy: A Systematic Review.
Bishev D, Fabara S, Loseke I, Alok A, Al-Ani H, Bazikian Y. Bishev D, et al. Heart Lung Circ. 2023 Sep;32(9):1049-1056. doi: 10.1016/j.hlc.2023.05.019. Epub 2023 Jul 14. Heart Lung Circ. 2023. PMID: 37453852 Free article. Review.
BACKGROUND: Current pharmacological options for hypertrophic cardiomyopathy (HCM) are not disease-specific; while it treats symptoms, mavacamten targets the underlying pathology. ...Three out of four studies demonstrated >1 NYHA functional class improvement rangi …
BACKGROUND: Current pharmacological options for hypertrophic cardiomyopathy (HCM) are not disease-specific; while it treats sy …
Atrial fibrillation and thromboembolism in patients with hypertrophic cardiomyopathy: systematic review.
Guttmann OP, Rahman MS, O'Mahony C, Anastasakis A, Elliott PM. Guttmann OP, et al. Heart. 2014 Mar;100(6):465-72. doi: 10.1136/heartjnl-2013-304276. Epub 2013 Sep 7. Heart. 2014. PMID: 24014282 Review.
OBJECTIVE: To critically review current literature on atrial fibrillation (AF) and thromboembolism in hypertrophic cardiomyopathy (HCM) and meta-analyse prevalence and incidence. ...Overall prevalence of thromboembolism in HCM patients with AF was 27.09% (95% CI 20. …
OBJECTIVE: To critically review current literature on atrial fibrillation (AF) and thromboembolism in hypertrophic cardiomyopathy …
74 results